{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"TriGemX Bio closes $94 million financing for Phase 3 migraine drug","author_name":"techandbusiness.org · Startups","thumbnail_url":"https://static.biospace.com/dims4/default/d32393a/2147483647/strip/true/crop/1120x630+40+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Fcc%2F88%2Fa9fddaf440db946b77e1d45d2e26%2Fbiospace-5.png","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Startups</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/AX4nAOr7JFnB9B_ktcUET-\" style=\"color:#fff;text-decoration:none;\">TriGemX Bio closes $94 million financing for Phase 3 migraine drug</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">TriGemX Bio announced it closed a $94 million financing to advance elismetrep, its investigational oral migraine treatment now in Phase 3 trials. The Column Group, TCGX and Viking Global Investors co-...</p>\n    </blockquote>"}